First Trust Advisors LP Has $43.85 Million Stake in Krystal Biotech, Inc. $KRYS

First Trust Advisors LP grew its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 11.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 248,392 shares of the company’s stock after acquiring an additional 26,022 shares during the period. First Trust Advisors LP owned 0.86% of Krystal Biotech worth $43,849,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of KRYS. Bessemer Group Inc. increased its holdings in Krystal Biotech by 106.9% during the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after purchasing an additional 77 shares in the last quarter. AdvisorNet Financial Inc acquired a new position in Krystal Biotech in the third quarter worth $30,000. Salomon & Ludwin LLC bought a new stake in shares of Krystal Biotech during the third quarter worth $33,000. First Horizon Advisors Inc. increased its stake in shares of Krystal Biotech by 212.8% in the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock valued at $34,000 after buying an additional 166 shares in the last quarter. Finally, Caldwell Trust Co acquired a new stake in shares of Krystal Biotech in the second quarter valued at $34,000. 86.29% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on KRYS. Weiss Ratings upgraded shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, February 18th. Jefferies Financial Group raised their price objective on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Citigroup boosted their target price on shares of Krystal Biotech from $336.00 to $371.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. HC Wainwright reissued a “buy” rating and set a $310.00 price target (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Finally, The Goldman Sachs Group raised their price target on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a report on Friday, January 30th. Nine research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $326.25.

Insider Buying and Selling at Krystal Biotech

In related news, Director Daniel Janney sold 11,803 shares of the stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $275.59, for a total value of $3,252,788.77. Following the transaction, the director directly owned 73,293 shares in the company, valued at $20,198,817.87. This represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $263.21, for a total transaction of $6,580,250.00. Following the completion of the transaction, the insider directly owned 1,403,155 shares in the company, valued at approximately $369,324,427.55. The trade was a 1.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 129,164 shares of company stock worth $34,538,578 in the last 90 days. Corporate insiders own 13.70% of the company’s stock.

Krystal Biotech Stock Down 2.3%

Krystal Biotech stock opened at $255.00 on Thursday. The business’s 50-day simple moving average is $270.39 and its 200 day simple moving average is $221.13. The stock has a market cap of $7.45 billion, a price-to-earnings ratio of 37.23 and a beta of 0.49. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $298.30.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.The firm had revenue of $107.11 million during the quarter, compared to analysts’ expectations of $105.30 million. As a group, sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.